IMS Pharmaceutical Pricing & Reimbursement Concise Guide: USA

  • ID: 1408501
  • Report
  • Region: North America, United States
  • 77 Pages
  • IMS Health
1 of 3
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.
Note: Product cover images may vary from those shown
2 of 3
1. HEALTHCARE SYSTEM
Facts & Figures
Market Indicators
Provision & Funding
Patient Protection and Affordable Care Act
Medicare
Medicaid
Uninsured

2. PRICING
Prescription Drugs
Price Controversies
Pricing Benchmarks
Private Payers
Medicare
Medicaid
Generic Drugs
Private Payers
Medicare
Medicaid
Hospital Drugs
Procurement
340B Drug Programme
OTC Drugs

3. REIMBURSEMENT
Admission to Reimbursement
Private Payers
Medicare
Medicaid
Other Federal Programmes
Reimbursement Categories
Private Payers
Medicare
Medicaid
Reimbursement Prices
Private Payers
Medicare
Medicaid
Hospital Reimbursement
Formularies
Private Payers
Medicare
Medicaid
340B Programme
Changes in Reimbursement Status
Private Payers
Medicare
Medicaid
Changes in Reimbursement Prices
Private Payers
Medicare
Medicaid

4. PHARMACOECONOMICS
Pharmacoeconomic Requirements
Private Payers
Medicare
Medicaid
Patient-Centered Outcomes Research Institute

5. PRICE BUILD UP
Wholesalers
Margins
Background
Retail Pharmacies
Margins
Dispensing Fees
Background
Dispensing Doctors
Sales Tax
Prescription Drugs
OTC Drugs

6. COST CONTAINMENT
Industry Paybacks
Annual Fees
User Fees
Promotional Costs
Advertising
Payments to Physicians
Patient Co-payments
Private Payers
Medicare
Medicaid
Pharmaceutical Assistance Programmes
Uninsured
Prescribing Controls
Formularies
Utilisation Controls
Off-label Prescribing
Monitoring
Other Initiatives
Generics
Measures to Boost Generic Uptake
Barriers to Generic Uptake
Biosimilars
Rx-to-OTC Switches
Switching Process
OTC Sales
Parallel Trade
Re-importation

7. FUTURE DEVELOPMENTS
Outlook
Healthcare Reform
Drug Pricing Proposals
Medicare Part D Price Negotiations
Medicare Part B Reimbursement Reform
Medicaid Rebate
State-level Action on Drug Pricing
MAC Transparency

8. NAMES & ADDRESSES
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll